Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) stock jumped 0.49% on Friday to $6.18 against a previous-day closing price of $6.15. With 0.83 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.68 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $6.83 whereas the lowest price it dropped to was $5.78. The 52-week range on BDRX shows that it touched its highest point at $1142.08 and its lowest point at $3.51 during that stretch. Beta for the stock currently stands at 1.94.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BDRX was down-trending over the past week, with a drop of -5.65%, but this was up by 17.94% over a month. Three-month performance dropped to -0.71% while six-month performance fell -94.28%. The stock lost -99.45% in the past year, while it has lost -98.04% so far this year.
Float and Shares Shorts:
At present, 0.53 million BDRX shares are outstanding with a float of 0.53 million shares on hand for trading. On Aug 30, 2023, short shares totaled 21530.0, which was 9.10% higher than short shares on Jul 30, 2023. In addition to Mr. Stephen A. Stamp as the firm’s CEO, CFO, Company Sec. & Director, Dr. Dmitry Zamoryakhin M.D. serves as its Chief Scientific Officer.
Through their ownership of 0.86% of BDRX’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 3.54% of BDRX, in contrast to 0.00% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in BDRX with 1.41% of the stake, Cubist Systematic Strategies LLC holds 3,325 shares worth 3,325. A second-largest stockholder of BDRX, Millennium Management LLC, holds 2,554 shares, controlling over 1.08% of the firm’s shares. UBS Securities LLC is the third largest shareholder in BDRX, holding 1,778 shares or 0.75% stake. With a 0.00% stake in BDRX, the Fidelity Nasdaq Composite Index F is the largest stakeholder. A total of 4 shares are owned by the mutual fund manager.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BDRX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With BDRX analysts setting a high price target of $251,959.00 and a low target of $251,959.00, the average target price over the next 12 months is $251,959.00. Based on these targets, BDRX could surge 4076906.47% to reach the target high and rise by 4076906.47% to reach the target low. Reaching the average price target will result in a growth of 4076906.47% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.